Influence of Type of Cigarette on Peripheral versus Central Lung Cancer by Brooks, Daniel R. et al.
Influence of Type of Cigarette on Peripheral versus Central
Lung Cancer
Daniel R. Brooks,1 John H.M. Austin,2 Robert T. Heelan,3 Michelle S. Ginsberg,3 Victor Shin,5
Sara H. Olson, 4 Joshua E. Muscat,7 and Steven D. Stellman6
1
Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts;
2
Department of Radiology, Columbia




Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center;
5
Department of Radiology, St. Luke’s-Roosevelt Hospital;
6
Department of Epidemiology, Mailman School of Public Health,
Columbia University, New York, New York; and
7
Penn State Cancer Institute, Division of Population Sciences,
Penn State College of Medicine, Hershey, Pennsylvania
Abstract
Objectives: Adenocarcinoma has replaced squamous cell
carcinoma as the most common cell type of lung cancer in
the United States. It has been proposed that this shift is due
to the increased use of filter and lower-tar cigarettes,
resulting in increased delivery of smoke to peripheral
regions of the lungs, where adenocarcinoma usually occurs.
We reviewed radiologic data to evaluate the hypothesis that
tumors in smokers of cigarettes with lower-tar yield are
more likely to occur peripherally than tumors in smokers of
higher-yield cigarettes.
Methods: At two urban academic medical centers, we
reviewed computed tomographic scans, chest radiographs,
and medical records to assign tumor location (peripheral or
central) for 330 smokers diagnosed with carcinoma of the
lung between 1993 and 1999. We compared the proportion
of tumors in a peripheral versus central location by lifetime
filter use and average lifetime tar rating (<21 and z21 mg).
Results: Tumor location (69% peripheral and 31% central)
was unrelated to cigarette filter use. Smokers of cigarettes
with lower-tar ratings were more likely than those with
higher ratings to have peripheral rather than central tumors
(odds ratio, 1.76; 95% confidence interval, 0.89-3.47). When
restricted to subjects with adenocarcinoma or squamous cell
carcinoma, the odds ratio (95% confidence interval) was 2.31
(1.05-5.08).
Conclusions: Among cigarette smokers with lung cancer, use
of cigarettes with lower-tar yield was associated with
preferential occurrence of tumors in peripheral sites. Our
findings support the hypothesis that changes in smoking
associated with lower-tar cigarettes have led to a shift in the
location of smoking-related lung cancer. (Cancer Epide-
miol Biomarkers Prev 2005;14(3):576–81)
Introduction
In the mid-twentieth century, carcinoma of the lung (‘‘bron-
chogenic carcinoma’’) occurred primarily in the bronchial tree
(1-5), and squamous cell carcinoma (SCC) was the predomi-
nant cell type (6, 7). Over the past several decades, the
incidence of adenocarcinoma increased to the extent that it has
now replaced SCC as the most common cell type in the United
States and throughout much of the world (8-11). During this
period, the types of cigarettes used by smokers have also
changed. Fifty years ago, virtually all cigarettes were unfiltered
and high in tar. Tar and nicotine ratings of cigarettes, as
measured by the Federal Trade Commission (FTC) machine
testing procedure, have decreased substantially since that time
(12). Today, virtually all smokers in the United States use filter
cigarettes, and almost 90% use cigarettes rated as low in tar
(V15 mg/cigarette) and nicotine (V 0.8 mg/cigarette; ref. 13).
Investigators have proposed several mechanisms that
causally link these two historical trends (14-18). The one most
frequently proposed is based on the observation that many
smokers compensate for the lower yield of nicotine, the main
psychoactive agent in cigarette smoke, by increasing puff
frequency, volume, or duration (19-23). This behavior presum-
ably results in deeper inhalation and thereby enhances
delivery of carcinogenic compounds to peripheral regions of
the lungs, where adenocarcinoma commonly occurs (24).
A second hypothesis suggests that filters reduce the average
size of smoke particulates, favoring their deposition in the
periphery of the lungs (14, 18). According to either hypothesis,
the historical increase in the occurrence of adenocarcinoma is a
consequence of the increased delivery of smoke constituents to
more distal regions of the lungs. A third proposed mechanism
focuses not on the area of the lung to which the smoke is
preferentially delivered but rather on changes in the type of
tobacco in cigarettes that have resulted in increased nitrosa-
mine content (12). In animal studies, adenocarcinoma is the
predominant cell type of lung cancer caused by nitrosamines
found in tobacco (25).
Several studies have found that long-term smokers of filter
cigarettes are more likely than smokers of nonfilter cigarettes to
develop adenocarcinoma compared with SCC (18, 26-30),
while, to our knowledge, none have assessed the effect of
FTC tar rating on histologic-specific risk. The hypothesized
association between type of cigarette and tumor location can be
inferred only indirectly from these studies, with cell type acting
as a proxy for location. To evaluate directly the hypothesis that
carcinoma of the lung is more likely to occur in a peripheral
than in a central location among smokers of cigarettes with
lower FTC tar ratings compared with smokers of higher-yield
cigarettes, we reviewed findings from computed tomographic
(CT) scans and chest radiographs of patients with lung cancer
who had participated in a study of tobacco-related disease.
Methods
The study population was drawn from subjects who had been
diagnosed with lung cancer at the Memorial Sloan-Kettering
Cancer Center (MSKCC) or Columbia Presbyterian Medical
Center (CPMC) in New York City and had participated in the
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American Health Foundation (AHF) case-control study of
tobacco-related diseases, which was conducted between 1969
and 1999 at hospitals in several cities throughout the United
States. All patients provided written informed consent on
forms that were approved by the institutional review boards of
the AHF and the two hospitals. The AHF study has been
described in detail elsewhere (31, 32).
The current study was restricted to participants between
ages 30 and 80 years who had histologically confirmed
carcinoma of the lung, had smoked for at least 15 years, and
reported no tobacco use other than cigarettes. We included
MSKCC patients beginning in 1993 and CPMC patients
beginning in 1996 based on the earliest years radiologic studies
were available for retrospective review. A total of 490 subjects
(372 at MSKCC and 118 at CPMC) met the eligibility criteria, of
whom 412 (305 at MSKCC and 107 at CPMC) had sufficient
information to characterize use of filter cigarettes or average
tar rating as described in the next section.
We attempted to obtain information on tumor location for
the 412 subjects with sufficient exposure information. Because
of differences in institutional computer systems, we took
slightly different approaches at the two hospitals. At MSKCC,
we reviewed CT scans for the period within 6 months of
diagnosis and before the earliest reported date of surgical
therapy. If no CT scan was available, we attempted to locate
posteroanterior and lateral chest radiographs (CXR) from the
same time period. At CPMC, we first searched the comput-
erized medical record for reports of radiologic, surgical, or
pathologic data that might provide information about tumor
location. If there was no report or the report contained
insufficient information, we obtained the CT scan or CXR for
direct review. We located a total of 363 cases: CT scans
(n = 211) or CXR (n = 54) for 265 of the 305 (87%) potential
subjects at MSKCC and unequivocal medical record reports
(41 CT scan, 25 pathology, and 6 additional sources), CT scans
(n = 20), or CXR (n = 6) for 98 of the 107 (92%) potential
subjects at CPMC.
No standard definition of central and peripheral locations
of lung tumors has been employed across different studies.
We defined central tumors as those where the center of mass
was within the hilar structures and peripheral tumors as
those where the center of mass was within the parenchyma
and with no or minimal contact with hilar structures. Because
we were concerned with etiology rather than treatment
outcome, we used the center of geometric mass as a marker
for the presumed initial starting point of the tumor. If there
were tumors in both central and peripheral locations, we only
included cases in which one was clearly larger. We recorded
the lobe, location, and size (based on the longest diameter at
presentation) of the tumor for each case. Each report or
imaging study was reviewed by one of three radiologists,
each a subspecialist in thoracic imaging (J.H.M.A., R.T.H.,
and M.S.G.), who assigned each case to a category of central,
peripheral, or ambiguous location. All chest imaging studies
of those cases originally judged to be ambiguous (n = 53,
15%) were then reviewed by the three radiologists as a group
and resolved by consensus. Radiologists were blinded to
subjects’ smoking histories throughout the assignment
process.
We were able to assign central or peripheral location to the
tumors of 330 of the 363 (91%) cases with available clinical
data. We were unable to assign 33 cases because (a) the
location remained ambiguous after review, (b) there were
multiple lesions with relatively equal components in central
and peripheral locations, (c) no CT scan was available and the
CXR was insufficient, or (d) no primary tumor was apparent.
We were unable to determine the size of 14 of the 330 tumors
with assigned location, because their margins were obscured
either by postobstructive atelectasis or by compression
atelectasis caused by pleural effusion.
Exposure Assignment. Information for classifying subjects
according to filter cigarette use and FTC tar rating was derived
from a detailed lifetime smoking history elicited during the
original AHF study. Basic smoking information included age at
initiation, total duration, current smoking status, number of
years temporarily stopped smoking, and number of years since
quitting. In addition, participants provided a lifetime cigarette
brand history, including name and characteristics (filter/
nonfilter, menthol/nonmenthol, regular/light/ultralight, and
length), number of years smoked, and average number
of cigarettes per day for up to seven brands.
To calculate the average FTC rating of tar level for each
subject, we first identified which calendar years subjects
reported particular brands, working backward from the most
recent brand reported and taking into consideration years in
which no smoking occurred due to total or temporary cessation.
We then assigned a tar value for each year. Tar ratings were
taken from FTC reports, which were generally issued annually
beginning in 1967 (33). Before that time, Reader’s Digest issued
an occasional series of reports using a similar methodology
between 1957 and 1966 (34-39). Tar ratings for intervening years
not covered by FTC or Reader’s Digest reports were assigned by
linear interpolation. Values for years before 1957 were extended
back to the release date of each brand based on the assessment
that tar levels did not change appreciably before 1957 (40).
We were unable to assign tar values for all years for some
subjects, because they reported either insufficient detail, brands
for which no tar information was available, or using particular
brands before they were actually on the market. We calculated
the mean FTC tar rating for each subject by averaging the
assigned tar ratings across all years with an assigned value. We
did not include the 3 years before diagnosis in calculation of tar
means, because exposure within this timeframe was unlikely to
have had an impact on the occurrence of lung cancer (31). We
excluded all subjects for whom tar ratings were available for
<60% of their smoking history. In preliminary analyses, we
found that estimates based on z60% information were very
similar to those withz80% information; thus, we chose the 60%
cutoff point to increase the number of subjects available for
analysis. All 330 subjects with assigned tumor location could be
classified according to extent of filter cigarette use (nonfilter
only, filter only, or mixed); 272 (82%) had sufficient information
to calculate average FTC tar rating.
Statistical Analysis. We dichotomized average FTC tar
ratings at <21.0 and z21.0 mg to provide approximately equal
numbers of subjects in each category. We used unconditional
logistic regression to estimate the likelihood of having a tumor
in a peripheral location for lower-tar compared with higher-tar
smokers as well as for lifetime filter and mixed filter/nonfilter
compared with lifetime nonfilter smokers. Because this study
is restricted to subjects with lung cancer, the odds ratio (OR)
does not represent an estimate of the effect of tar level on the
occurrence of disease but can appropriately be interpreted as
the effect of FTC tar rating on the distribution of tumor
location (41, 42).
Estimates were adjusted for sex, age (<55, 55-59, 60-64,
65-69, or z70 years), and cell type (adenocarcinoma, SCC,
small cell carcinoma, large cell carcinoma, or other/
unknown). Cell type was determined at the time of the
original AHF study from surgical pathology reports
or cytologic findings. We also conducted analyses restricted
to adenocarcinoma and SCC, because the primary hypoth-
eses regarding tumor location have focused specifically
on historical changes in the distribution of these two cell
types (16-19). Finally, because prior studies have assessed
the association between type of cigarette and cell type
instead of location, we evaluated whether smokers with
lower FTC tar ratings were more likely than those with
higher ratings to develop adenocarcinoma than SCC.
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Results
Tumors were in the periphery of the lung in 69% of subjects
and in the hilar region in 31%. Adenocarcinoma was the most
common cell type (50% of all tumors), whereas SCC
accounted for 28%; 132 of the 166 (80%) adenocarcinomas
and 51 of the 93 (55%) SCCs were peripheral (v2 = 17.51;
P = 0.00003). The mean size of the 228 peripheral tumors
was 4.4 cm (SD = 2.5; range, 0.8-17.0) and the mean size of
the 102 central tumors was 5.4 cm (SD = 2.3; range, 1.0-12.7;
t = 3.33; P = 0.001). Subjects who were ages <55 years (n = 65)
were less likely than those age z55 years (n = 265) to have
peripheral tumors; otherwise, there were only minor differ-
ences in tumor location by demographic or smoking-related
characteristics (Table 1).
Differences in type of cigarette use were extensive but
consistent with the introduction of filter and lower-tar
cigarettes during the 1950s to 1970s: smokers with lower
average FTC tar ratings were much more likely to be female,
to be younger, to have smoked for fewer years, and to smoke
currently or to have recently quit. The demographic character-
istics of those who exclusively smoked filter cigarettes were
similar to those of lower-tar smokers.
There was no association between tumor location and either
extent of filter use or average tar rating as measured by the
crude OR (Table 2). Use of filter cigarettes remained
unassociated with tumor location after adjustment. However,
after adjusting for sex, age, and cell type, smokers of lower-tar
brands were more likely to have tumors in a peripheral than a
central location [OR, 1.76; 95% confidence interval (95% CI),
0.89-3.47]. There was little evidence of any difference between
men and women in the relationship between FTC tar rating
and tumor location (P for interaction = 0.54). The association
between lower-tar ratings and peripheral tumors was similar
among current (OR, 1.81; 95% CI, 0.66-4.98) and former
(OR, 2.09; 95% CI, 0.72-6.08) smokers.
When the analysis was restricted to subjects with adenocar-
cinoma and SCC only, the adjusted association between lower-
tar rating and peripheral location was even stronger (OR, 2.31;
95% CI, 1.05-5.08; Table 2). Lower-tar smokers were also more
likely to have a tumor in a peripheral location whether the cell
type was adenocarcinoma (OR, 2.85; 95% CI, 0.82-9.95) or SCC
(OR, 2.29; 95% CI, 0.77-6.87).
We evaluated the reasons for the substantial difference
between the crude (0.96) and adjusted (1.76) OR estimates for
the effect of tar level on tumor location. Age had the strongest
effect on the estimate; adjusting for age alone raised the OR to
1.43, which accounted for two thirds of the difference between
crude and fully adjusted estimates. Adjusting for cell type, in
addition to age, further increased the OR to 1.71. Age was not
simply a proxy for smoking duration; adjusting for duration
alone only increased the OR to 1.14, and substituting duration
for age in the full model produced an estimate of 1.34.
Because almost all (97%) subjects ages <55 years (n = 58) were
in the lower-tar category, we repeated analyses limited to
subjects who were ages z55 years (n = 272). For this subgroup,
the crude OR for the likelihood of peripheral tumors
among smokers of lower-tar cigarettes was 1.35, which was
Table 1. Smoking history by type of cigarette and location of lung tumors by subject characteristics
Smoking history* Tumor locationc
Lifetime filter use Average FTC tar rating (mg) Peripheral, n (%) Central, n (%)
Filter only, n (%) Mixed and nonfilter, n (%) <21, n (%) z21, n (%)
Overall 138 (42) 192 (58) 139 (51) 133 (49) 228 (69) 102 (31)
Cell type
Adenocarcinoma 73 (44) 93 (56) 69 (53) 63 (47) 132 (80) 34 (20)
SCC 32 (34) 61 (66) 35 (45) 42 (55) 51 (55) 42 (45)
Small cell 6 (46) 7 (54) 7 (64) 4 (36) 3 (23) 10 (77)
Large cell 5 (56) 4 (44) 2 (29) 5 (71) 7 (78) 2 (22)
Otherb 22 (45) 27 (55) 26 (58) 19 (42) 35 (71) 14 (29)
Size (cm)x
V3 43 (47) 48 (53) 40 (52) 37 (48) 77 (85) 14 (15)
>3-6 60 (38) 99 (62) 66 (52) 62 (48) 102 (64) 57 (36)
>6 28 (42) 38 (58) 28 (50) 28 (50) 40 (61) 26 (39)
Sex
Male 60 (33) 123 (67) 68 (43) 91 (57) 126 (69) 57 (31)
Female 78 (53) 69 (47) 71 (63) 42 (37) 102 (69) 45 (31)
Age (y)
<55 49 (75) 16 (25) 56 (97) 2 (3) 38 (58) 27 (42)
55-59 23 (40) 35 (60) 29 (60) 19 (40) 41 (71) 17 (29)
60-64 21 (35) 39 (65) 23 (44) 29 (56) 43 (72) 17 (28)
65-69 23 (31) 51 (69) 16 (28) 42 (72) 54 (73) 20 (27)
z70 22 (30) 51 (70) 15 (27) 41 (73) 52 (71) 21 (29)
Years smoked
<40 88 (56) 70 (44) 87 (66) 44 (34) 104 (66) 54 (34)
z40 50 (29) 122 (71) 52 (37) 89 (63) 124 (72) 48 (28)
Cigarettes/dk
<25 67 (46) 80 (54) 52 (46) 61 (54) 100 (68) 47 (32)
z25 71 (39) 110 (61) 87 (55) 72 (45) 126 (70) 55 (30)
Years quit smoking
0 (current) 81 (59) 94 (41) 88 (60) 58 (40) 118 (67) 57 (33)
1-5 18 (36) 32 (64) 24 (56) 19 (44) 36 (72) 14 (28)
6-15 26 (43) 34 (57) 24 (46) 28 (54) 42 (70) 18 (30)
>15 13 (29) 32 (71) 3 (10) 28 (90) 32 (71) 13 (29)
*Information was sufficient to determine extent of filter cigarette use for 330 subjects and average tar rating for 272 subjects.
cAs determined by review of imaging studies or other information in the medical record.
bIncludes other miscellaneous types and nonclassified.
xSize was not determined for 14 subjects. See text for details.
kInformation was insufficient to determine the number of cigarettes per day for two subjects.
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substantially higher than the crude OR for all ages (OR, 0.96).
The adjusted OR (95% CI) among subjects ages z55 years was
1.75 (0.87-3.53), virtually identical to the estimate based on
subjects of all ages. When restricted to subjects with adenocar-
cinoma or SCC, the adjusted OR (95% CI) was 2.53 (1.12-5.73).
We did not find a greater occurrence of adenocarcinoma
than SCC for lower-tar compared with higher-tar smokers
(OR, 0.66; 95% CI, 0.33-1.35) nor for lifetime filter compared
with lifetime nonfilter smokers (OR, 1.26; 95% CI, 0.55-2.91).
Discussion
The main result of the present study is that smokers of cigarettes
with lower average FTC tar ratings who developed carcinoma
of the lung were more likely to develop tumors in a peripheral
rather than in a central location compared with smokers of
cigarettes with higher average tar ratings. This result is
consistent with the theory that the altered inhalation pattern
observed in smokers of cigarettes that are lower in tar and
nicotine as measured by machine smoking results in increased
delivery of carcinogens to the periphery of the lungs and
thereby in an associated shift in the distribution of location of
origin of smoking-related lung cancers (11, 17-19).
Prior evidence for this theory has relied primarily on the
general relationship between tumor histology and location.
First, there has been a shift in the predominant cell type of lung
cancer from SCC (which tends to occur centrally) to adeno-
carcinoma (which commonly occurs peripherally) during the
same time period that filter use has been increasing and
average FTC tar ratings have been falling (8-11). Second, some
studies have found that long-term filter smokers were more
likely to develop adenocarcinoma than SCC compared with
smokers of nonfilter cigarettes (18, 26-30). In the present study,
we were able to show a direct association between cigarette tar
yield and tumor location, which was strongest among patients
with adenocarcinoma or SCC.
It is interesting to note that we did not find an association
between FTC tar ratings and cell type despite the relationship
between tar rating and location. One possible explanation for
this apparent paradox is that the correlation between tumor cell
type and location may not be as strong as sometimes assumed.
In our study, 80% of the adenocarcinomas occurred peripher-
ally, but only 45% of the SCCs occurred in a central location.
Although the relationship between tumor histology and
location may have been straightforward in the mid-twentieth
century (43, 44), more recent studies have described consider-
able proportions of SCC in a peripheral location (39-59%; refs.
45-47) as well as adenocarcinoma in a central location (41-60%;
refs. 48-50). In addition, studies may differ due to different
definitions and methodologies for determining central and
peripheral locations.
Although the mechanism for the increased occurrence of
peripheral lung tumors in smokers of lower-yield cigarettes
is presumed to be the enhanced delivery of smoke to peripheral
regions of the lung, we are not aware of any studies that
directly demonstrate this phenomenon. Numerous experimen-
tal and observational studies have shown that smokers of
lower-yield cigarettes as measured by machine smoking use a
variety of strategies that maximize the inhalation of nicotine
and tar from each cigarette, including covering filter ventila-
tion holes with lips or fingers, taking more puffs, and
increasing puff size (19-23). Although it perhaps may be
inferred that the larger puff volumes observed among smokers
of low-yield cigarettes imply deeper inhalation, the dynamics
of deposition of cigarette smoke in the lung are complex and
do not necessarily follow simple predictive models (51, 52).
Cigarette filters trap larger particles in smoke, thereby
reducing the median diameter of the particles inhaled (14, 18),
which should favor peripheral particulate deposition among
filter compared with nonfilter cigarette smokers (53). There-
fore, it is perhaps surprising that we did not find any
association between lifetime filter use and tumor location.
However, laboratory simulations suggest that the mass
of particles in inhaled cigarette smoke behaves as a single,
larger entity rather than according to their constituent
characteristics (54). Therefore, particle size may be a less
important determinant of deposition site than predicted by
models that are based on the diameter of individual particles.
The design characteristics of lower-yield cigarettes may also
offset to some degree the effect of filters in reducing particle
size of inhaled smoke. Lower-yield cigarettes partially rely on
ventilation holes in the filter, which allow ambient air to dilute
the smoke, to reduce their standardized machine ratings (22).
Increased ventilation increases the particle size of smoke,
which would counteract the effect of the filter in reducing
particle size (55).
Because our study was limited to cases only, it would be
erroneous to conclude that the results necessarily mean that
smokers of cigarettes with lower FTC tar ratings have a higher
risk of peripheral lung cancer than do higher-tar smokers.
Rather, the results indicate that smokers who do develop lung
cancer are more likely to have a peripheral than a central tumor if
they smoked cigarettes with lower average tar rating compared
with the distribution of location among higher-tar smokers.
We suggest that the clarification of etiologic mechanisms
may be a more important result of this study than clinical
implications for individual patients. Overall 5-year survival
remains very poor for lung cancer, and there is little difference
in 5-year survival rates between patients with central and
peripheral tumors (56, 57). At the same time, survival is better
for early-stage tumors which are V3 cm compared with >3 cm
in diameter (58), and 35% of peripheral tumors in our study
were V3 cm compared with 14% of tumors in a central location.
Other cigarette constituents might play an important role in
determining tumor location. Although our analyses were based
on filter use and FTC tar ratings, the amount of smoke delivered
to the peripheral region of the lung may be determined in
Table 2. Association among filter cigarette use, average FTC tar rating, and tumor location


















Only nonfilterc 32 14 1 1 27 11 1 1
Mixed 103 43 1.05 1.19 (0.55-2.58) 79 34 0.95 0.91 (0.39-2.15)
Only filter 93 45 0.90 1.16 (0.52-2.63) 73 30 0.99 1.12 (0.44-2.83)
Mean tar level (mg)
z21c 91 42 1 1 67 35 1 1
<21 94 45 0.96 1.76 (0.89-3.47) 72 30 1.25 2.31 (1.05-5.08)
*Adjusted for sex, age, and cell type.
cReference group.
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greater measure by nicotine than by tar. However, nicotine and
tar ratings are generally highly correlated and have tracked
closely over time; therefore, use of either FTC tar or nicotine
ratings would likely produce very similar results. The average
nicotine/tar ratios within categories of brands rated as high,
low, and ultralow in tar in 1984 were 14, 12.6, and 11.4,
respectively (12). We also found an extremely high correlation
(r = 0.98) among a representative group of U.S. brands based on
1996 ratings (59).
Inreased levels of nitrosamines in lower-tar cigarettes might
also be at least partly responsible for changes in tumor histology
and, indirectly, location (12, 25). Nitrosamine levels in cigarettes
are not necessarily correlated with tar or nicotine ratings (12)
and therefore might produce different results. However,
analysis of nitrosamines has never been required by the FTC,
and publicly available data are very sparse, making it impos-
sible to reconstruct brand-specific nitrosamine levels over time.
Some limitations of the present study need to be considered.
Information on FTC tar ratings came from self-reported recall
of a lifetime history of brand names, associated characteristics,
and number of years each brand was smoked. Interviewers at
both hospitals were trained and supervised by the same AHF
personnel, and similar quality control procedures for data
collection and management were in place at both institutions.
Nevertheless, we did not specifically measure the reliability of
recall of lifetime brand history and there is bound to be some
degree of misclassification in our exposure measure. However,
misclassification should be nondifferential (i.e., not associated
with tumor location) and so should bias our estimate toward
the null.
There is also likely to be some misclassification in
determining tumor location. Fifteen percent of cases were
sufficiently ambiguous to require review, and a greater
percentage of these were assigned to peripheral location
(89%) than among cases not requiring review (66%). However,
when we excluded cases requiring review, the OR for
peripheral tumors among lower-tar smokers increased (2.24
versus 1.76). We also had to use CXR instead of CT scans for
16% of cases. Cases based on review of CXR were somewhat
less likely to be assigned to peripheral location (60%) than
were cases assigned by CT scans or other sources (71%).
However, when we excluded cases assigned by CXR, the
estimates for the effect of FTC tar rating on location were
virtually the same as when all cases were included.
The substantial difference between crude and adjusted
analyses of FTC tar ratings and tumor location is also a cause
for concern. The confounding effect of age, particularly among
those ages <55 years, was the main contributor to this
difference. As expected, younger smokers were much more
likely than older smokers to have had a lower average FTC tar
rating, but (counterintuitively) they were also more likely to
have central rather than peripheral tumors. Our results did not
change when the analysis was restricted to those ages z55
years, but additional studies would help determine the reason
for the age-related change in estimate.
In summary, we found that smokers of cigarettes with lower
FTC tar ratings had relatively more tumors in a peripheral
location than did smokers of cigarettes with higher-tar levels.
These results provide support for the theory that the decrease
in nicotine and tar levels as measured by machine smoking
over time has caused smokers to adopt a pattern of deeper
inhalation, which has resulted in increased exposure
of peripheral lung tissue to tobacco smoke and a consequent
shift to the periphery in the site of origin of lung cancers.
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